SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. IBM
10. HOOD

Go back to SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression

Raymond James Reiterates Outperform Rating on Johnson & Johnson (JNJ)

January 22, 2025 8:15 AM EST

Raymond James analyst Jayson Bedford reiterated an Outperform rating and $170.00 price target on Johnson & Johnson (NYSE: JNJ)

The analyst comments "Quick take: 4Q results were solid with a 1% revenue beat and a 3% EPS beat. The revenue upside was driven by Innovative Medicine... More